Chemical Compounding Injectable Anticancer Market - Forecast(2021 - 2026)

Report Code: HCR 1470 Report Format: PDF + Excel (Delivery in 48 Hrs)

Chemical Compounding Injectable Anticancer Market Overview

Chemical compounding injectable anticancer market size was valued at $140,315 million in 2020, and is anticipated to grow at a CAGR of 6.05% during the forecast period 2021-2026. The chemical compounding injectable anticancer industry growth rate is attributed to the increasing health care awareness followed by a rapid growth in chronic diseases across the world and are poised in bringing new opportunities. Chemical compounding injectable anticancer refers to the intravenous drugs that are infused in the body during cancer treatment. These injectable affect the development of cancer-inducing proteins while also destroying cancerous cells. Injectable oncology medications, which are commonly used to treat different cancers, offer improved effectiveness, higher bioavailability, less gastrointestinal discomfort, and greater compliance. The factors driving the growth of the market for chemical compounding injectable anticancer include increased global prevalence of cancer, along with a greater awareness of early diagnosis, which is encouraging manufacturers of injectable anticancer drugs to invest heavily in research and development could affect the growth of the market for chemical compounding injectable anticancer. Apart from this, the widespread availability of modern medical infrastructure, as well as simple access to chemotherapy treatments followed by faster drug approvals from various regulatory bodies, such as the U.S. Food and Drug Administration (FDA) is also offering the manufacturers lucrative growth opportunities over the forecast period 2021-2026. However, challenges in storage, packaging, and distribution of anticancer chemical injectable coupled with the stringent rules and regulations for manufacturing in certain regions are also poised to be one of the factors negatively affecting the chemical compounding injectable anticancer market penetration. 

Report Coverage

The report: “Chemical Compounding Injectable Anticancer Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Chemical Compounding Injectable Anticancer Market:
By Type: Chemical and Others.
By Role: Injectable and Others.
By Class: Alkylating Agents, Antimetabolites and Others.
By Geography: North America (U.S., Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Russia and Others), APAC (China, Japan, India, South Korea, Australia and Others), South America(Brazil, Argentina and Others) and RoW (Middle East and Africa).

Key Takeaways

  • The factors such as increasing demand for effective and convenient drug delivery system by consumers are amongst the major factor projected to impel growth of chemical compounding injectable anticancer market.
  • Additionally, factors such as availability of modern medical infrastructure, as well as simple access to chemotherapy treatments followed by faster drug approvals from various regulatory bodies create opportunities paving a way for the growth in the market during forecast period 2021-2026.


Chemical Compounding Injectable Anticancer Market Segment Analysis - By Role
Chemical Compounding Injectable Anticancer Market
For More Details on This Report - Request for Sample

Chemical Compounding Injectable Anticancer Market Segment Analysis - By Role

In 2020, on the basis of role, injectable segment accounted for the largest segmental revenue of the chemical compounding injectable anticancer market. The injectable segment held the largest market as these drug delivery systems use technologically advanced and smarter systems, on account of wider scope such as injecting the drug at the target site allowing it to be more localized. Moreover, injectable is the fastest growing segment by role with a CAGR of 6.8% during the forecast period of 2021-2026 as there is an increasing demand for effective and convenient drug delivery system by consumers, which is poised to create lucrative opportunity for the manufacturers to manufacture such effective injectable thereby, responsible for their high demand.

Chemical Compounding Injectable Anticancer Market Segment Analysis - By Class

On the basis of class, alkylating agents segment accounted for the largest segmental revenue of the chemical compounding injectable anticancer market in 2020. The large share can be attributed to the rich promising pipeline of drugs coupled with rising trend amongst the market players for the ample availability of such injectable products is attributed to positively affect market growth during the forecast period 2021-2026 owing to launches of drugs annually and advances in pharmaceuticals and biotechnological sectors or industries. 

On the other hand, antimetabolite segment is projected to dominate over the forecast period 2021-2026 with a CAGR of 6.34%. The antimetabolite segment is to witness a surge in growth owing to the increase in research and developmental activities worldwide over the last decade as presence of these drugs has a negative impact on cell cycles owing that these drugs stop the cell growth and division. Apart from this, there are initiatives to create awareness about the usage of this drug in the cancer diagnosis through increased government funding for R&D is anticipated to positively impact the growth of this segmental market during the forecast period 2021-2026.

Chemical Compounding Injectable Anticancer Market Segment Analysis - By Geography

North America is the major region dominating the chemical compounding injectable anticancer market with a market share of 37.90% in the year 2020. This is owing to the region witnessed steady developments coupled with rising health consciousness amongst the customers demanding innovative medical technologies. Furthermore, there is also a rise in the geriatric population which is followed by a surge in chronic and autoimmune diseases in the region, to contribute significantly to the growth of the chemical compounding injectable anticancer market in North America.

However, Asia-Pacific is projected to be the significant-growing market during the forecast period 2021-2026. This is attributed to the untapped opportunities in developing countries that are projected to encourage the growth of the Asia Pacific market for chemical compounding injectable anticancer drugs owing to growing health care expenditure. Furthermore, governments in these nations have put on a focus regarding the increasing awareness about novel drugs followed by targeting global pharmaceutical companies towards investing in the developing economies has also contributed significantly to the region’s growth.

Chemical Compounding Injectable Anticancer Market Drivers

Increasing Launches Of Drugs 

The chemical compounding injectable anticancer market is poised to receive upswing owing to the rapid increase in demand for chemical injectable anticancer owing to the increasing health care awareness, consumers are shifting their focus toward development for effective and convenient drug delivery system that have contributed significantly to the growth of the demand for chemical compounding injectable anticancer market. 

Greater Effort From Government

The growth in the chemical compounding injectable anticancer industry is owing to the fact that governments in the developing nations have put on a focus regarding the increasing awareness about novel drugs followed by targeting global pharmaceutical companies towards investing in the developing economies which is projected to foster the market growth of chemical injectable anticancer drugs. 

Chemical Compounding Injectable Anticancer Market Challenges

Stringent Rules And Regulations

One of the major factors lowering the chemical compounding injectable anticancer is owing to the stringent rules and regulations for manufacturing in certain regions which might pose a big challenge for the key players. Furthermore, manufacturing challenges in storage, packaging, and distribution of chemical injectable drugs are factors restraining the global market growth.

Chemical Compounding Injectable Anticancer Market Landscape

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the chemical compounding injectable anticancer market. In 2020, chemical compounding injectable anticancer market share is fragmented by the top ten players present in the market. The Chemical Compounding Injectable Anticancer market top 10 companies are Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC., Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Pfizer Inc. and others.

Acquisitions/Product Launches

  • In December 2019, Dr. Reddy's Laboratories Ltd. launched Bortezomib for Injection 3.5 mg/vial, indicated for the treatment of certain types of cancers in adult patients, in the U.S. market. The company launched Bortezomib for Injection 3.5 mg/vial, approved by the United States Food and Drug Administration via a new drug application pathway for intravenous use only, Dr. Reddy's Laboratories.
  • In September 2019, Mylan N.V. launched Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, a generic version of AstraZeneca's Faslodex Injection, for the treatment of advanced breast cancer in the U.S. 

Relevant Reports:

Report Code: HCR 0023

Report Code: HCR 0718

For more Lifesciences and Healthcare Market reports, please click here
1. Chemical Compounding Injectable Anticancer Market - Overview
    1.1 Definitions and Scope
2. Chemical Compounding Injectable Anticancer Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Type
    2.3 Key trends by Class
    2.4 Key trends by Geography
3. Chemical Compounding Injectable Anticancer Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Chemical Compounding Injectable Anticancer Market - Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Chemical Compounding Injectable Anticancer Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Chemical Compounding Injectable Anticancer Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Chemical Compounding Injectable Anticancer Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Chemical Compounding Injectable Anticancer Market – By Type (Market Size –$Million/$Billion)
    8.1 Chemical
    8.2 Others
9. Chemical Compounding Injectable Anticancer Market - By Role (Market Size –$Million/$Billion)
    9.1 Injectable
    9.2 Others
10. Chemical Compounding Injectable Anticancer Market - By Class (Market Size –$Million/$Billion)
    10.1 Alkylating Agents
    10.2 Antimetabolites
    10.3 Others
11. Chemical Compounding Injectable Anticancer Market - By Geography(Market Size –$Million/$Billion) 
    11.1 North America
        11.1.1 U.S.
        11.1.2 Mexico
        11.1.3 Canada
    11.2 Europe
        11.2.1 U.K.
        11.2.2 France
        11.2.3 Germany
        11.2.4 Russia
        11.2.5 Italy
        11.2.6 Spain
        11.2.7 Rest of Europe
    11.3 Asia Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of APAC
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Others
    11.5 Rest of the World
        11.5.1 Middle East
        11.5.2 Africa
        11.5.3 South America
12. Chemical Compounding Injectable Anticancer Market - Entropy
13. Chemical Compounding Injectable Anticancer Market – Industry/Segment Competition Landscape Premium 
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Best Practices for Companies
14. Chemical Compounding Injectable Anticancer Market – Key Company List by Country Premium Premium
15. Chemical Compounding Injectable Anticancer Market Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.